Proactive Investors - Run By Investors For Investors

Shield Therapeutics' Feraccru drug 'a potential game-changer'

Capital Network analyst Riccardo Lowi discusses Shield Therapeutics PLC’s (LON:STX) lead asset Feraccru - a novel and highly differentiated iron formulation, for oral administration, indicated for the treatment of iron deficiency.

US regulators have set a target date for a decision on whether or not to approve it by 27 July 2019.

 
Meet Manolete Partners PLC, Arkle Resources PLC, Royal Road Minerals and Neo Lithium Corp at our event, London , 04 April 2019. Register here »
View full STX profile View Profile

Shield Therapeutics PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use